Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
116 participants
INTERVENTIONAL
2016-04-24
2016-05-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Manufacturing Technology
NCT03962790
Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses
NCT04529109
Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses (2022)
NCT05480514
Evaluation of Three Daily Disposable Contact Lenses
NCT02568254
Clinical Study of Approved and Investigational Contact Lenses
NCT02708524
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group Sequence A, B, C
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Etafilcon A Design 1 (Test 1)
Etafilcon A Design 2 (Test 2)
Etafilcon A (Control)
Group Sequence B, C, A
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Etafilcon A Design 1 (Test 1)
Etafilcon A Design 2 (Test 2)
Etafilcon A (Control)
Group Sequence C, A, B
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Etafilcon A Design 1 (Test 1)
Etafilcon A Design 2 (Test 2)
Etafilcon A (Control)
Group Sequence C, B, A
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Etafilcon A Design 1 (Test 1)
Etafilcon A Design 2 (Test 2)
Etafilcon A (Control)
Group Sequence A, C, B
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Etafilcon A Design 1 (Test 1)
Etafilcon A Design 2 (Test 2)
Etafilcon A (Control)
Group Sequence B, A, C
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Etafilcon A Design 1 (Test 1)
Etafilcon A Design 2 (Test 2)
Etafilcon A (Control)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etafilcon A Design 1 (Test 1)
Etafilcon A Design 2 (Test 2)
Etafilcon A (Control)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The subject's vertex corrected best spherical distance refraction must be in the range of -1.00 to -6.00 Diopters (D) in each eye.
3. The subject's vertex corrected cylindrical component of distance refraction must be less than or equal to -1.50 Diopters of Cylinder (DC) in each eye.
4. Subjects must have best corrected visual acuity of 20/25 (Snellen or equivalent) or better in each eye.
5. Subjects must self-report as being Asian race.
6. Subjects must self-report as having brown or black eyes.
7. Subjects must be habitual lens wearer (clear or limbal ring cosmetic) . Habitual is defined as at least one (1) month of Contact Lens wear where the lenses were worn for a minimum of six (6) hours per day and a minimum of three (3) days per week.
8. Subjects between 18 to 39 years old must be habitual limbal ring cosmetic lens wearers or must have tried limbal ring cosmetic lens within the past two years.
9. Subjects must be cosmetic contact lens concept acceptors as determined by screening questionnaire.
10. Subjects must possess a functional / usable pair of spectacles and bring them to the visit (only if applicable - to the investigator's discretion).
11. Subjects must read, understand, and sign the Statement of Informed Consent.
12. Subjects must appear able and willing to adhere to the instructions set forth in the clinical protocol.
13. Subjects must be willing to have their eyes video recorded and photographed.
Exclusion Criteria
2. Participated in any paid market research within the past 3 months.
3. Pregnant or breast feeding a baby.
4. Subjects with diabetes.
5. Any ocular or systemic allergies or disease which might interfere with contact lens wear.
6. Any systemic disease, or autoimmune disease, which might interfere with contact lens wear, at investigator's discretion.
7. Using medications during and immediately preceding the study period that may interfere with current contact lens wear as determined by the investigators
8. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report.
9. Any grade 3 or greater Biomicroscopy findings (this includes, corneal edema, corneal staining, corneal vascularization, conjunctival injection, tarsal abnormalities, bulbar injection) on the FDA classification scale.
10. Any active ocular abnormalities/conditions that might interfere with contact lens wear (this includes, but not limited to, chalazia, recurrent styles, pterygium, infection etc.).
11. Any corneal distortion, scar, or opacity affecting vision as noted by subjects or investigators during examination.
12. History of any corneal surgery (e.g. radial keratotomy (RK), photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK)); confirmed with topography if necessary at the investigator's discretion.
13. Habitual wearers of rigid gas permeable or orthokeratology lens within the past 3 months.
14. Current habitual contact lens modality for extended wear or conventional wear (contact lenses with a replacement schedule of 3 months to \>1 year).
15. Participation in any pharmaceutical, medical device, or contact lens related clinical research trial within 14 days prior to study enrollment. This excludes studies that do not require product treatment/intervention.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Vision Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hong Kong Polytechnic University
Hong Hom, Kowloon, Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-5759
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.